P Reichardt

Summary

Affiliation: HELIOS Klinikum Wuppertal
Country: Germany

Publications

  1. ncbi request reprint Novel approaches to imatinib- and sunitinib-resistant GIST
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin Brandenburg, Pieskower Strasse 33, 15526 Bad Saarow, Germany
    Curr Oncol Rep 10:344-9. 2008
  2. ncbi request reprint Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
    Eva Wardelmann
    Department of Pathology, University of Bonn Medical School, Bonn, Germany
    Clin Cancer Res 12:1743-9. 2006
  3. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
  4. doi request reprint Optimal use of targeted agents for advanced gastrointestinal stromal tumours
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    Oncology 78:130-40. 2010
  5. doi request reprint Current questions in soft tissue sarcoma: further steps with Yondelis®
    Peter Reichardt
    Helios Klinikum Berlin Buch, Department of Interdisciplinary Oncology, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Expert Rev Anticancer Ther 13:25-30. 2013
  6. doi request reprint Adjuvant therapy in primary GIST: state-of-the-art
    P Reichardt
    Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:2776-81. 2012
  7. doi request reprint Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
    P Reichardt
    HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin Brandenburg, Bad Saarow, Germany
    Ann Oncol 23:1680-7. 2012
  8. doi request reprint Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management
    Peter Reichardt
    HELIOS Klinikum Bad Saarow GmbH, Germany
    Expert Rev Anticancer Ther 12:1053-68. 2012
  9. doi request reprint [Internal medical therapy of gastrointestinal stroma tumors]
    P Reichardt
    Klinik fur Innere Medizin III, Sarkomzentrum Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, Bad Saarow, Germany
    Radiologe 49:1128-31. 2009
  10. doi request reprint Towards global consensus in the treatment of gastrointestinal stromal tumor
    Peter Reichardt
    Department of Hematology, Oncology and Palliative Medicine, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Expert Rev Anticancer Ther 10:221-32. 2010

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Novel approaches to imatinib- and sunitinib-resistant GIST
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin Brandenburg, Pieskower Strasse 33, 15526 Bad Saarow, Germany
    Curr Oncol Rep 10:344-9. 2008
    ....
  2. ncbi request reprint Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
    Eva Wardelmann
    Department of Pathology, University of Bonn Medical School, Bonn, Germany
    Clin Cancer Res 12:1743-9. 2006
    ..According to our results, the identification of newly acquired KIT mutations in addition to the primary mutation is dependent on the number of tissue samples analyzed and has high implications for further therapeutic strategies...
  3. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  4. doi request reprint Optimal use of targeted agents for advanced gastrointestinal stromal tumours
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    Oncology 78:130-40. 2010
    ..Individualisation of therapy may help to maximise clinical benefit of therapy in these patients...
  5. doi request reprint Current questions in soft tissue sarcoma: further steps with Yondelis®
    Peter Reichardt
    Helios Klinikum Berlin Buch, Department of Interdisciplinary Oncology, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Expert Rev Anticancer Ther 13:25-30. 2013
    ..Trabectedin has made possible new models of care, such as long-term treatment and rechallenge. Its use has also fueled important and necessary debate about the criteria currently used to evaluate tumor response...
  6. doi request reprint Adjuvant therapy in primary GIST: state-of-the-art
    P Reichardt
    Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:2776-81. 2012
    ..The objectives of this European Expert Panel meeting were to describe the optimal management and best practice for the systemic adjuvant treatment of patients with primary GISTs...
  7. doi request reprint Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
    P Reichardt
    HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin Brandenburg, Bad Saarow, Germany
    Ann Oncol 23:1680-7. 2012
    ..This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure...
  8. doi request reprint Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management
    Peter Reichardt
    HELIOS Klinikum Bad Saarow GmbH, Germany
    Expert Rev Anticancer Ther 12:1053-68. 2012
    ..The benefits of multidisciplinary disease management of patients include reducing recurrent disease, optimizing timing of surgery and organ preservation, prolonging survival for the patient and enhancing response to targeted therapies...
  9. doi request reprint [Internal medical therapy of gastrointestinal stroma tumors]
    P Reichardt
    Klinik fur Innere Medizin III, Sarkomzentrum Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, Bad Saarow, Germany
    Radiologe 49:1128-31. 2009
    ..Locally advanced GIST should be treated with systemic therapy prior to surgical resection. Imatinib was recently licensed for adjuvant therapy following complete surgical removal of GIST in patients with a significant risk of recurrence...
  10. doi request reprint Towards global consensus in the treatment of gastrointestinal stromal tumor
    Peter Reichardt
    Department of Hematology, Oncology and Palliative Medicine, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Expert Rev Anticancer Ther 10:221-32. 2010
    ..A summary of consensus across these guidelines based on clinical trial data is juxtaposed with expert opinion where gaps in data still remain...
  11. ncbi request reprint Molecular targeted therapy of gastrointestinal stromal tumors
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin Brandenburg, Pieskower Strasse 33, 15526 Bad Saarow, Germany
    Curr Cancer Drug Targets 11:688-97. 2011
    ....
  12. doi request reprint [Gastrointestinal stromal tumour (GIST): current standards in multimodal management]
    P Reichardt
    HELIOS Klinkum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Pieskower Strasse 33, Bad Saarow, Germany
    Zentralbl Chir 136:359-63. 2011
    ..After exploitation of all registered therapy options the patients should be offered an experimental therapy within the framework of a clinical trial...
  13. doi request reprint [Systemic therapy of soft tissue sarcomas]
    D Pink
    Klinik für Innere Medizin III mit Schwerpunkt Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Str 33, 15526 Bad Saarow, Deutschland
    Pathologe 32:65-71. 2011
    ..The first and highly successful targeted therapy was seen with the introduction of imatinib in the treatment of gastrointestinal stromal tumors...
  14. doi request reprint Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib
    O Dudeck
    Department of Radiology, HELIOS Clinic Berlin Buch, Berlin, Germany
    Ann Oncol 22:1828-33. 2011
    ..Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST)...
  15. doi request reprint The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
    D Andreou
    Department of Orthopedic Oncology, Helios Klinikum Berlin Buch, Academic Teaching Hospital of the Charité Universitätsmedizin, Berlin
    Ann Oncol 22:1228-35. 2011
    ..Local recurrence (LR) in osteosarcoma is associated with very poor prognosis. We sought to evaluate which factors correlate with LR in patients who achieved complete surgical remission with adequate margins...
  16. ncbi request reprint The treatment of uterine sarcomas
    P Reichardt
    Department of Interdisciplinary Oncology, Sarcoma Center Berlin Brandenburg, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:x151-7. 2012
    ..Endometrial stromal sarcomas are usually hormonal receptor positive, which allows endocrine therapy in most cases...
  17. doi request reprint Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
    P Hohenberger
    Division of Surgical Oncology and Thoracic Surgery, Oncology and Palliative Care, Helios Medical Centre, Bad Saarow, Germany
    Br J Surg 97:1854-9. 2010
    ..This study assessed the outcomes of patients with a gastrointestinal stromal tumour (GIST) that ruptured before or during resection...
  18. doi request reprint Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}
    P C Thuss-Patience
    Department of Haematology, Oncology and Tumorimmunology, Campus Virchow Klinikum, Charite University Medicine Berlin, Berlin, Germany
    Ann Oncol 23:2827-34. 2012
    ..This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma...
  19. ncbi request reprint Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors
    G Reich
    , Campus Berlin-Buch, , Department of Hematology, Oncology and Tumor Immunology, Humboldt University of Berlin, Germany
    Bone Marrow Transplant 27:525-9. 2001
    ..6% of patients with documented infections. With respect to the incidence, type and clinical course of infection, no significant differences between patients with lymphoma or multiple myeloma and those with solid tumors were detected...
  20. doi request reprint Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues
    Peter Reichardt
    Sarcoma Center Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    Semin Oncol 36:290-301. 2009
    ..The biological features of GIST make it a model for the examination of kinase-targeted therapeutics in solid tumors...
  21. ncbi request reprint Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    John R Zalcberg
    Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Eur J Cancer 41:1751-7. 2005
    ..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy...
  22. ncbi request reprint Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI
    Christian Stroszczynski
    Klinik und Poliklinik für Strahlenheilkunde, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
    Eur Radiol 15:2448-56. 2005
    ..01), when compared with non-responders. Beyond the size measurement for response assessment, MRI provides additional information of tumour response using SI of T2-w images and quantification of vascularised areas of GIST manifestations...
  23. ncbi request reprint Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases
    Daniel Pink
    J Clin Oncol 23:6809-11. 2005
  24. ncbi request reprint Imatinib and altered bone and mineral metabolism
    Heikki Joensuu
    N Engl J Med 355:628; author reply 628-9. 2006
  25. ncbi request reprint Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr
    Martine van Glabbeke
    EORTC Data Center, Av E Mounier, 83, Bte 8, B1200, Brussels, Belgium
    Eur J Cancer 42:2277-85. 2006
    ..A multivariate risk calculator that can be used in the clinic for individual patients is proposed...
  26. ncbi request reprint Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  27. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    Pierre Fumoleau
    Cancer 98:1325-6; author reply 1326-7. 2003
  28. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008